ClinicalTrials.gg
Active, not recruitingNCT02123758Updated Nov 3, 2026

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of Abiraterone Acetate and Prednisone in Prostatic Neoplasms and Metastatic Castration-Resistant Prostate Cancer, sponsored by Aragon Pharmaceuticals, Inc.. Active, not recruiting at 7 sites in 4 countries. Open to male participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Aragon Pharmaceuticals, Inc. (part of Johnson & Johnson) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
18 Years to 99 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms — 12 open to participants now, 29 under way, 4 of them phase 3. Abiraterone Acetate · Prostatic Neoplasms.

Enrollment
48th of 98
57 · median 56
Started
2014
with 9 others
Phase 1
16 of 98
none open now
Primary completion
2016-06
later than 0 of 28 live
Registered
40th of 98
by date

Among the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, this one is the 48th largest by enrollment, is one of 10 that started in 2014, is one of 16 in phase 1, reaches primary completion later than 0 of the 28 other live ones, and was the 40th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

12 of the 98 studies testing Abiraterone Acetate in Prostatic Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About Abiraterone Acetate

Abiraterone Acetate: first FDA approval 2011 (ZYTIGA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 99 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing Abiraterone Acetate in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927.

Read the detailed description

This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone [AAP] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment [ie, for up to an expected duration of approximately 18 months] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and to complete the PK analysis up to the cutoff date. All participants will continue on study (ie, to receive treatment) until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. The end of the study is defined when all participants have completed treatment. Participant's safety will be monitored throughout the study.

03

Conditions studied

  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • Prostatic Neoplasms
  • Metastatic Castration-Resistant Prostate Cancer (mCRPC)
  • Prostate cancer
  • Abiraterone Acetate (ZYTIGA)
  • Prednisone
  • JNJ-56021927
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) performance status less than or equal to (\<=) 2
  • or cytologically confirmed adenocarcinoma of the prostate
  • Documentation of disease
  • Prostate cancer progression
  • Surgically or medically castrated, with testosterone levels of less than (\<) 50 nanogram per deciliter (ng/dL)
  • Adequate bone marrow and organ function

Exclusion criteria

Exclusion Criteria:

  • Known
  • Pathological finding consistent with small cell carcinoma of the prostate
  • Administration of an agent within 4 weeks of Treatment Cycle 1, Day 1
  • Chemotherapy, or immunotherapy for the treatment of prostate cancer within 4 weeks of Treatment Cycle 1, Day 1
  • Therapies that must be discontinued or substituted prior to Treatment Cycle 1, Day 1 include the following: Medications known to lower the seizure threshold; Herbal and non-herbal products that may decrease prostate specific antigen (PSA) levels (that is, saw palmetto, pomegranates or pomegranate juice); Medications known to induce drug metabolizing enzymes such as dexamethasone, rifampicin, carbamazepine, phenytoin, phenobarbital, St. John's wort, etc.; and, potent inhibitors of or CYP2C8
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of abiraterone acetate + prednisone (AAP) + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AA and prednisone. Breakfast will be offered approximately 30 minutes after intake of JNJ-56021927. Treatment cycles will be of 28 days.

    Drug: Abiraterone Acetate · Drug: Prednisone · Drug: JNJ-56021927

  • Experimental
    Cohort 2

    Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.

    Drug: Abiraterone Acetate · Drug: Prednisone · Drug: JNJ-56021927

Interventions

  • Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

    Also known as: ZYTIGA

  • Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

  • Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of abiraterone

    The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.

    Time frame: Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)

  2. Maximum plasma concentration (Cmax) of abiraterone, prednisone and its metabolite prednisolone

    The Cmax is the maximum observed plasma concentration.

    Time frame: Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)

  3. Area Under the Plasma Concentration-time Curve From Time Zero to Time 12 Hours (AUC [0-12]) of prednisone and its metabolite prednisolone

    The AUC (0-12) is area under the plasma concentration-time curve from time zero to time 12 hours.

    Time frame: Day 7 (Treatment Cycle 1) and on Day 36 (Treatment Cycle 2)

Secondary outcomes

  1. Area Under the Plasma Concentration Curve (AUC [0- 24h]) of JNJ-56021927 and its metabolite JNJ-56142060

    The AUC (0-24) is area under the plasma concentration-time curve from time zero to time 24 hours.

    Time frame: Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)

  2. Maximum plasma concentration (Cmax) of JNJ-56021927 and its metabolite JNJ-56142060

    The Cmax is the maximum observed plasma concentration.

    Time frame: Day 36 (Treatment Cycle 2), on Day 57 (Treatment Cycle 3)

  3. Change in prostate specific antigen (PSA)

    Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.

    Time frame: Up to the end of the treatment phase (approximately 18 months)

  4. Maximal decline in prostate specific antigen (PSA)

    Prostate-specific antigen (PSA) is a protein produced by cells of the prostate gland.

    Time frame: Up to the end of the treatment phase (approximately 18 months)

07

Study locations

7 sites
  • Los Angeles, California, United States
  • San Francisco, California, United States
  • Houston, Texas, United States
  • Vancouver, British Columbia, Canada
  • Montreal, Quebec, Canada
  • Rotterdam, Netherlands
  • Sutton, United Kingdom
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2014 to primary completion in Jun 2016, 23 months.

Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 23 months is below that.

Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2014
First posted
Apr 28, 2014
StartActual
Jul 9, 2014
Primary completionActual
Jun 27, 2016
CompletionEst.
Dec 31, 2027
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 3, 2026
Show all 2 updates
  1. Nov 3, 2026
    Minor edits only
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02123758
Responsible party
Sponsor
First posted
Apr 28, 2014
Start date
Jul 9, 2014
Primary completion
Jun 27, 2016
Completion
Dec 31, 2027 (estimated)
Last update
Nov 3, 2026

Study contacts

Aragon Pharmaceuticals, Inc. Clinical Trial
study director · Aragon Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate · Apalutamide

Start the discussion